146 related articles for article (PubMed ID: 36567345)
21. Methylation of FOXP3 in regulatory T cells is related to the severity of coronary artery disease.
Jia L; Zhu L; Wang JZ; Wang XJ; Chen JZ; Song L; Wu YJ; Sun K; Yuan ZY; Hui R
Atherosclerosis; 2013 Jun; 228(2):346-52. PubMed ID: 23566804
[TBL] [Abstract][Full Text] [Related]
22. All-Trans Retinoic Acid Induces CD4+CD25+FOXP3+ Regulatory T Cells by Increasing FOXP3 Demethylation in Systemic Sclerosis CD4+ T Cells.
Sun X; Xiao Y; Zeng Z; Shi Y; Tang B; Long H; Kanekura T; Wang J; Wu H; Zhao M; Lu Q; Xiao R
J Immunol Res; 2018; 2018():8658156. PubMed ID: 29854846
[TBL] [Abstract][Full Text] [Related]
23. Naturally occurring CD4+ CD25+ FOXP3+ T-regulatory cells are increased in chronic myeloid leukemia patients not in complete cytogenetic remission and can be immunosuppressive.
Rojas JM; Wang L; Owen S; Knight K; Watmough SJ; Clark RE
Exp Hematol; 2010 Dec; 38(12):1209-18. PubMed ID: 20854875
[TBL] [Abstract][Full Text] [Related]
24. Peripheral whole blood FOXP3 TSDR methylation: a potential marker in severity assessment of autoimmune diseases and chronic infections.
Ngalamika O; Liang G; Zhao M; Yu X; Yang Y; Yin H; Liu Y; Yung S; Chan TM; Lu Q
Immunol Invest; 2015; 44(2):126-36. PubMed ID: 25083793
[TBL] [Abstract][Full Text] [Related]
25. Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor-Sensitive and -Resistant Chronic Myeloid Leukemia.
Ben-Batalla I; Erdmann R; Jørgensen H; Mitchell R; Ernst T; von Amsberg G; Schafhausen P; Velthaus JL; Rankin S; Clark RE; Koschmieder S; Schultze A; Mitra S; Vandenberghe P; Brümmendorf TH; Carmeliet P; Hochhaus A; Pantel K; Bokemeyer C; Helgason GV; Holyoake TL; Loges S
Clin Cancer Res; 2017 May; 23(9):2289-2300. PubMed ID: 27856601
[No Abstract] [Full Text] [Related]
26. Methylation-Sensitive Restriction Enzyme Quantitative Polymerase Chain Reaction Enables Rapid, Accurate, and Precise Detection of Methylation Status of the Regulatory T Cell (Treg)-Specific Demethylation Region in Primary Human Tregs.
Perry N; Wasko K; Cheng J; Tabbaa D; Marco E; Giannoukos G; Albright CF; Borges CM
J Immunol; 2021 Jan; 206(2):446-451. PubMed ID: 33277386
[TBL] [Abstract][Full Text] [Related]
27. Flow cytometry and targeted immune transcriptomics identify distinct profiles in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors with or without interferon-α.
Alves R; McArdle SEB; Vadakekolathu J; Gonçalves AC; Freitas-Tavares P; Pereira A; Almeida AM; Sarmento-Ribeiro AB; Rutella S
J Transl Med; 2020 Jan; 18(1):2. PubMed ID: 31900171
[TBL] [Abstract][Full Text] [Related]
28. Induction of CD4
Khosravi M; Bidmeshkipour A; Cohen JL; Moravej A; Hojjat-Assari S; Naserian S; Karimi MH
Stem Cell Res Ther; 2018 Oct; 9(1):273. PubMed ID: 30359308
[TBL] [Abstract][Full Text] [Related]
29. Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.
Shiseki M; Yoshida C; Takezako N; Ohwada A; Kumagai T; Nishiwaki K; Horikoshi A; Fukuda T; Takano H; Kouzai Y; Tanaka J; Morita S; Sakamoto J; Sakamaki H; Inokuchi K
Int J Clin Oncol; 2017 Oct; 22(5):972-979. PubMed ID: 28550414
[TBL] [Abstract][Full Text] [Related]
30. FOXP3 promoter demethylation reveals the committed Treg population in humans.
Janson PC; Winerdal ME; Marits P; Thörn M; Ohlsson R; Winqvist O
PLoS One; 2008 Feb; 3(2):e1612. PubMed ID: 18286169
[TBL] [Abstract][Full Text] [Related]
31. Hypomethylation at the regulatory T cell-specific demethylated region in CD25hi T cells is decoupled from FOXP3 expression at the inflamed site in childhood arthritis.
Bending D; Pesenacker AM; Ursu S; Wu Q; Lom H; Thirugnanabalan B; Wedderburn LR
J Immunol; 2014 Sep; 193(6):2699-708. PubMed ID: 25092890
[TBL] [Abstract][Full Text] [Related]
32. The antiproliferative activity of kinase inhibitors in chronic myeloid leukemia cells is mediated by FOXO transcription factors.
Pellicano F; Scott MT; Helgason GV; Hopcroft LE; Allan EK; Aspinall-O'Dea M; Copland M; Pierce A; Huntly BJ; Whetton AD; Holyoake TL
Stem Cells; 2014 Sep; 32(9):2324-37. PubMed ID: 24806995
[TBL] [Abstract][Full Text] [Related]
33. Targeted De-Methylation of the FOXP3-TSDR Is Sufficient to Induce Physiological FOXP3 Expression but Not a Functional Treg Phenotype.
Kressler C; Gasparoni G; Nordström K; Hamo D; Salhab A; Dimitropoulos C; Tierling S; Reinke P; Volk HD; Walter J; Hamann A; Polansky JK
Front Immunol; 2020; 11():609891. PubMed ID: 33488615
[TBL] [Abstract][Full Text] [Related]
34. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.
Zeng X; Zhao H; Li Y; Fan J; Sun Y; Wang S; Wang Z; Song P; Ju D
Autophagy; 2015; 11(2):355-72. PubMed ID: 25701353
[TBL] [Abstract][Full Text] [Related]
35. Hypoxia-inducible factor 1α inhibitor induces cell death via suppression of BCR-ABL1 and Met expression in BCR-ABL1 tyrosine kinase inhibitor sensitive and resistant chronic myeloid leukemia cells.
Tsubaki M; Takeda T; Matsuda T; Kimura A; Tanaka R; Nagayoshi S; Hoshida T; Tanabe K; Nishida S
BMB Rep; 2023 Feb; 56(2):78-83. PubMed ID: 36195570
[TBL] [Abstract][Full Text] [Related]
36. Down-regulation of Tet2 is associated with Foxp3 TSDR hypermethylation in regulatory T cell of allergic rhinitis.
Tan L; Qiu T; Xiang R; Cao C; Deng Y; Tao Z; Xu Y
Life Sci; 2020 Jan; 241():117101. PubMed ID: 31778687
[TBL] [Abstract][Full Text] [Related]
37. Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes.
McClymont SA; Putnam AL; Lee MR; Esensten JH; Liu W; Hulme MA; Hoffmüller U; Baron U; Olek S; Bluestone JA; Brusko TM
J Immunol; 2011 Apr; 186(7):3918-26. PubMed ID: 21368230
[TBL] [Abstract][Full Text] [Related]
38. Chronic myeloid leukaemia patients at diagnosis and resistant to tyrosine kinase inhibitor therapy display exhausted T-cell phenotype.
Harrington P; Dillon R; Radia D; McLornan D; Woodley C; Asirvatham S; Raj K; Curto-Garcia N; Saunders J; Kordasti S; Harrison C; de Lavallade H
Br J Haematol; 2022 Sep; 198(6):1011-1015. PubMed ID: 35802024
[TBL] [Abstract][Full Text] [Related]
39. Human LAP
Wang H; Song H; Pham AV; Cooper LJ; Schulze JJ; Olek S; Tran DQ
Theranostics; 2019; 9(8):2315-2324. PubMed ID: 31149046
[TBL] [Abstract][Full Text] [Related]
40. Which method better evaluates the molecular response in newly diagnosed chronic phase chronic myeloid leukemia patients with imatinib treatment, BCR-ABL(IS) or log reduction from the baseline level?
Qin YZ; Jiang Q; Jiang H; Li JL; Li LD; Zhu HH; Lai YY; Lu XJ; Liu YR; Jiang B; Huang XJ
Leuk Res; 2013 Sep; 37(9):1035-40. PubMed ID: 23810191
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
